Teva sidelines Valeant with $6.8bn Cephalon bid
Wednesday, May 4, 2011 - 09:50
in Earth & Climate
The move increases product diversity at the generics giant and strengthens its branded products portfolio
Updated by artificial intelligence Tue, 13 Jun 2023, 2:53:47 UTC Learn more
- Tell your friends
- Get science news via